Who is eligible for clinical trial NCT04157348?

Participants must meet protocol criteria for Eosinophilic Granulomatous Vasculitis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04157348 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-20

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (NCT04157348)

A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).

Who can join: Review the eligibility criteria below.

Location: Research Site — Denver, Colorado

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (50 Sites)

Showing the first 25 of 50 sites.

Research Site — Denver, Colorado
Research Site — Ann Arbor, Michigan
Research Site — Rochester, Minnesota
Research Site — Albuquerque, New Mexico
Research Site — Great Neck, New York
Research Site — New York, New York
Research Site — Philadelphia, Pennsylvania
Research Site — Denison, Texas
Research Site — Seattle, Washington
Research Site — Brussels,
Research Site — Brussels,
Research Site — Calgary, Alberta
Research Site — Hamilton, Ontario
Research Site — Toronto, Ontario
Research Site — Toronto, Ontario
Research Site — Dijon,
Research Site — Marseille,
Research Site — Montpellier,
Research Site — Nantes,
Research Site — Paris,
Research Site — Paris,
Research Site — Suresnes,
Research Site — Toulouse,
Research Site — Bamberg,
Research Site — Freiburg im Breisgau,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Eosinophilic Granulomatous Vasculitis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗